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1. INTRODUCTION {#dom12832-sec-0005}
===============

Over the past decade, dipeptidyl peptidase‐4 (DPP‐4) inhibitors have become an established therapy for the treatment of patients with type 2 diabetes (T2DM).[1](#dom12832-bib-0001){ref-type="ref"}, [2](#dom12832-bib-0002){ref-type="ref"} Omarigliptin (MK‐3102) is a selective oral DPP‐4 inhibitor with a half‐life that enables once‐weekly dosing[3](#dom12832-bib-0003){ref-type="ref"} and was recently approved in Japan.

The DPP‐4 inhibitor class of drugs improve glycaemic control in patients with T2DM by slowing the inactivation of incretin hormones, including glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP), which are part of an endogenous system involved in the physiological regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP‐1 and GIP increase insulin synthesis in, and release from, pancreatic β cells. GLP‐1 also lowers glucagon secretion from pancreatic α cells. The action of these incretins is glucose‐dependent, such that when glucose levels are low, enhancement of insulin secretion and inhibition of glucagon release are not observed, a mechanism associated with a low incidence of hypoglycaemia.[1](#dom12832-bib-0001){ref-type="ref"}

In the present study, we report the results of a clinical study that compared the glycaemic efficacy and safety of the addition of omarigliptin 25 mg administered once weekly with the addition of sitagliptin 100 mg administered once daily in patients with inadequate glycaemic control on metformin monotherapy.

2. MATERIALS AND METHODS {#dom12832-sec-0006}
========================

2.1. Patients {#dom12832-sec-0007}
-------------

Eligible patients were men and women (aged ≥18 years) with T2DM who had been on a stable dose of metformin (≥1500 mg/d) for ≥12 weeks and had a glycated haemoglobin (HbA1c) concentration ≥6.5% and ≤9.0% at screening and a fasting fingerstick glucose \>7.2 and \<14.4 mmol/L at randomization. Patients were excluded from the study if they had type 1 diabetes, a history of ketoacidosis, active liver disease, significant cardiovascular disease, a history of malignancy or haematological disorders, or if they had been previously treated with any antihyperglycaemic agents other than metformin within 12 weeks prior to screening or with omarigliptin at any time before signing informed consent. For patients assessed by the investigator as possibly having type 1 diabetes, C‐peptide level was measured, and patients with a fasting C‐peptide level \<0.7 ng/mL (0.23 nmol/L) were excluded.

Laboratory exclusion criteria included creatinine levels ≥124 µmol/L (men) or ≥115 µmol/L (women) (≥1.4 or ≥1.3 mg/dL), estimated glomerular filtration rate \<60 mL/min/1.73 m^2^ (calculated by the Modification of Diet in Renal Disease formula), serum alanine aminotransferase or aspartate aminotransferase levels \>2 times the upper limit of normal (ULN), triglycerides \>6.8 mmol/L (\>600 mg/dL) or thyroid‐stimulating hormone outside the central laboratory normal range.

2.2. Study design {#dom12832-sec-0008}
-----------------

The study was a multinational, double‐blind, double‐dummy, randomized, active‐controlled, non‐inferiority trial conducted in 97 sites in 13 countries (6 in Argentina, 6 in Canada, 1 in Croatia, 5 in Estonia, 5 in Georgia, 10 in Hungary, 4 in Israel, 5 in Malaysia, 4 in the Philippines, 9 in Poland, 8 in Romania, 8 in South Africa and 26 in the USA). The study included a 1‐week screening period, a 2‐week single‐blind placebo run‐in period and a 24‐week double‐blind treatment period (Figure S1). After the run‐in period, patients were randomized centrally, using an interactive voice response system, in a 1:1 ratio to omarigliptin 25 mg once weekly (and placebo matching sitagliptin, dosed once daily) or sitagliptin 100 mg once daily (and placebo matching omarigliptin, dosed once weekly). Patients not meeting progressively stricter prespecified glycaemic control criteria post‐randomization (from day 1 through week 6, fasting plasma glucose \[FPG\] \>14.99 mmol/L; from week 6 to week 12, FPG \>13.32 mmol/L; after week 12 through week 24 \>11.10 mmol/L) were rescued with open‐label glimepiride. The study (MK‐3102‐026; [ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT01841697) was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. Informed consent was obtained from all study participants.

2.3. Study evaluations {#dom12832-sec-0009}
----------------------

The primary objectives of the present study were assessment of the efficacy, safety and tolerability of 24 weeks of omarigliptin treatment. The primary study hypothesis was that the mean change from baseline in HbA1c in patients treated with omarigliptin once weekly would be non‐inferior to that in patients treated with sitagliptin once daily.

Secondary objectives were to assess the effect of the addition of omarigliptin compared with sitagliptin on FPG and on the percentage of patients with HbA1c of \<7.0% and \<6.5% after 24 weeks of treatment.

2.4. Efficacy endpoints {#dom12832-sec-0010}
-----------------------

Efficacy endpoints were changes from baseline in HbA1c and FPG after 24 weeks of treatment. The percentages of patients who reached HbA1c goals of \<7.0% and \<6.5% at week 24 were also calculated.

2.5. Safety endpoints {#dom12832-sec-0011}
---------------------

Safety assessment included collection of adverse events (AEs), physical examination, including vital signs, standard laboratory blood chemistry (eg, liver and renal safety tests), lipid panel, haematology, urine analysis and ECG. In addition, amylase and lipase levels were measured as per regulatory agency request. A standard questionnaire was provided to patients to collect hypoglycaemia information.

Potential cases of pancreatitis (events assessed by the investigator as possibly being pancreatitis, or events meeting prespecified event terms suggestive of pancreatitis) and prespecified hypersensitivity AEs (anaphylactic reaction, angioedema, asthma‐bronchospasm, erythema multiforme, Stevens‐Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms) were evaluated in a blinded manner by external clinical adjudication committees.

2.6. Statistical analyses {#dom12832-sec-0012}
-------------------------

All randomized patients who received at least one dose of study treatment and had a baseline or a post‐randomization measurement served as the primary population for efficacy analyses. For analyses of the primary efficacy endpoint, a constrained longitudinal data analysis (cLDA) model[4](#dom12832-bib-0004){ref-type="ref"} including terms for treatment, time and the interaction of time by treatment with the restriction of a common baseline mean across treatment groups was used. The primary hypothesis regarding the non‐inferiority of omarigliptin vs sitagliptin in decreasing HbA1c was assessed using the estimated treatment difference from the cLDA model. If the upper bound of the two‐sided 95% confidence interval (CI) for the mean difference between omarigliptin and sitagliptin was less than the non‐inferiority margin (δ = 0.3%), then omarigliptin was declared non‐inferior to sitagliptin. Data acquired after the initiation of rescue therapy were treated as missing to avoid the confounding influence of rescue therapy. FPG level was analysed using the cLDA model described above for HbA1c, substituting the FPG baseline efficacy measurement for HbA1c. Analysis of percentages of individuals at the HbA1c goals of \<7.0% and \<6.5% at week 24 was based on estimated rates and CIs for between‐group rate differences computed using the Miettinen and Nurminen method,[5](#dom12832-bib-0005){ref-type="ref"} stratified by baseline HbA1c (\> or ≤ median).

Analysis of safety data used the population of all randomized patients who received at least one dose of study treatment. Safety and tolerability were assessed during the treatment period and through 21 days after treatment, which ended by clinical review of all relevant variables, including AEs, laboratory tests, ECG, vital signs and body weight. Safety data acquired after initiation of glycaemic rescue medication were excluded from the primary analysis. AEs of symptomatic hypoglycaemia were prespecified as events of interest and *P* values and 95% CIs for between‐treatment group comparisons were calculated. For AEs with incidence of at least 4 patients in any treatment group, change from baseline in body weight, any AE of hypoglycaemia and AEs of severe hypoglycaemia, 95% CIs were calculated for between‐group comparisons using the method of Miettinen and Nurminen.[5](#dom12832-bib-0005){ref-type="ref"} For body weight, change from baseline was analysed using the cLDA method described above, substituting baseline body weight for HbA1c.

Using a standard deviation of 0.96% and assuming the true mean difference in HbA1c between omarigliptin and sitagliptin is 0.0% (α = 0.05, two‐sided test), and factoring for expected missing data, 300 randomized patients per treatment group would provide 95.7% power to declare non‐inferiority with a margin = 0.3% in HbA1c reduction at week 24.

3. RESULTS {#dom12832-sec-0013}
==========

3.1. Patient disposition and characteristics {#dom12832-sec-0014}
--------------------------------------------

A total of 985 patients were screened and 642 were randomized (322 to omarigliptin and 320 to sitagliptin). The most common reasons for a patient not being randomized were not meeting the prior antihyperglycaemic therapy and HbA1c requirements or meeting exclusionary laboratory values. The first dose of study medication was administered on June 20, 2013 and the last patient visit was on November 17, 2014.

Of the 642 randomized patients, 588 (91.6%) completed the study on study medication (Figure S2). Baseline demographics and efficacy variables were generally balanced between treatment groups (Table [1](#dom12832-tbl-0001){ref-type="table-wrap"}). The mean age was 57.3 years, \~50% were male, the mean body mass index was 32 kg/m^2^ and the mean duration of diabetes was 7 years.

###### 

Baseline demographic, anthropometric and disease characteristics of study treatment groups

                                  **Omarigliptin**   **Sitagliptin**
  ------------------------------- ------------------ -----------------
  Age, years                      57 ± 10            58 ± 10
  Male, n (%)                     151 (46.9)         175 (54.7)
  Race, n (%)                                        
  White                           257 (79.8)         248 (77.5)
  Asian                           32 (9.9)           44 (13.8)
  Black                           26 (8.1)           24 (7.5)
  Multi‐racial                    6 (1.9)            3 (0.9)
  Pacific Islander                1 (0.3)            0 (0.0)
  American Indian/Alaska Native   0 (0.0)            1 (0.3)
  Ethnicity, n (%)                                   
  Not Hispanic or Latino          253 (78.6)         257 (80.3)
  Hispanic or Latino              49 (15.2)          52 (16.3)
  Not reported                    12 (3.7)           7 (2.2)
  Unknown                         8 (2.5)            4 (1.3)
  Body weight, kg                 91.3 ± 20.1        87.7 ± 16.9
  Body mass index, kg/m^2^        32.7 ± 6.1         31.3 ± 5.1
  HbA1c, %                        7.5 ± 0.8          7.5 ± 0.7
  FPG, mmol/L                     8.9 ± 2.0          8.5 ± 1.8
  Duration of T2DM, years         7.0 ± 4.5          7.5 ± 5.6

Values are mean ± standard deviation unless otherwise noted.

3.2. Efficacy {#dom12832-sec-0015}
-------------

After 24 weeks, the LS mean change from baseline in HbA1c was −0.47% (95% CI −0.55, −0.38) with omarigliptin 25 mg once weekly and −0.43% (95% CI −0.51, −0.35) with sitagliptin 100 mg once daily (Figure [1](#dom12832-fig-0001){ref-type="fig"}A and Table [2](#dom12832-tbl-0002){ref-type="table-wrap"}). The between‐group LS mean difference in change from baseline at week 24 in HbA1c was ‐0.03% (95% CI −0.15, 0.08), with the upper bound of the 2‐sided 95% CI for the between‐group difference below the prespecified non‐inferiority margin of 0.3%. The time course profile for the change in HbA1c was similar for the 2 treatment groups (Figure [1](#dom12832-fig-0001){ref-type="fig"}A). Most of the treatment effect on HbA1c was observed by week 12 for both agents and the effect was maintained throughout the remainder of the treatment period. Subgroup analyses by baseline HbA1c showed greater reductions in HbA1c in patients with higher baseline HbA1c (Table [2](#dom12832-tbl-0002){ref-type="table-wrap"}). In the subgroup with baseline HbA1c ≥8.0% (mean 8.6% for omarigliptin and 8.5% for sitagliptin) the reduction in HbA1c from baseline was −0.79% (95% CI −0.99, −0.58) and −0.71% (95% CI −0.91, −0.51) for the omarigliptin and sitagliptin groups, respectively.

![Efficacy measures until week 24. A, Change from baseline HbA1c (%) and B, change from baseline FPG (mmol/L), based on a model with terms for treatment, prior antihyperglycaemic therapy status (yes/no), and the interaction of time by treatment, and time by prior antihyperglycaemic therapy status, with a constraint that the mean baseline was the same for both treatment groups. Black circles: omarigliptin; white circles: sitagliptin. s.e., standard error.](DOM-19-394-g001){#dom12832-fig-0001}

###### 

Efficacy endpoints at week 24

                                                                 **Omarigliptin**       **Sitagliptin**
  -------------------------------------------------------------- ---------------------- ----------------------
  HbA1c, %                                                                              
  Full analysis set                                                                     
  Baseline                                                       7.5 ± 0.8              7.5 ± 0.7
  Week 24                                                        7.0 ± 0.9              7.0 ± 0.8
  Change from baseline[1](#dom12832-note-0005){ref-type="fn"}    −0.47 (−0.55, −0.38)   −0.43 (−0.51, −0.35)
  Change vs sitagliptin[2](#dom12832-note-0006){ref-type="fn"}   −0.03 (−0.15, 0.08)    
  Subgroup: baseline HbA1c \<7.0%                                n = 87                 n = 87
  Baseline                                                       6.6 ± 0.3              6.6 ± 0.2
  Week 24                                                        6.3 ± 0.5              6.4 ± 0.5
  Change from baseline[1](#dom12832-note-0005){ref-type="fn"}    −0.28 (−0.37, −0.18)   −0.18 (−0.28, −0.09)
  Change vs sitagliptin[2](#dom12832-note-0006){ref-type="fn"}   −0.09 (−0.23, 0.04)    
  Subgroup: baseline HbA1c ≥7.0% and \<8.0%                      n = 149                n = 145
  Baseline                                                       7.4 ± 0.3              7.4 ± 0.3
  Week 24                                                        7.0 ± 0.8              6.9 ± 0.6
  Change from baseline[1](#dom12832-note-0005){ref-type="fn"}    −0.39 (−0.51, −0.27)   −0.40 (−0.53, −0.28)
  Change vs sitagliptin[2](#dom12832-note-0006){ref-type="fn"}   0.01 (−0.16, 0.19)     
  Subgroup: baseline HbA1c ≥8.0%                                 n = 86                 n = 88
  Baseline                                                       8.6 ± 0.4              8.5 ± 0.3
  Week 24                                                        7.7 ± 0.9              7.7 ± 1.0
  Change from baseline[1](#dom12832-note-0005){ref-type="fn"}    −0.79 (−0.99, −0.58)   −0.71 (−0.91, −0.51)
  Change vs sitagliptin[2](#dom12832-note-0006){ref-type="fn"}   −0.08 (−0.37, 0.21)    
  FPG, mmol/L                                                                           
  Full analysis set                                                                     
  Baseline                                                       8.9 ± 2.0              8.5 ± 1.8
  Week 24                                                        7.9 ± 1.9              8.0 ± 1.8
  Change from baseline[1](#dom12832-note-0005){ref-type="fn"}    −0.8 (−1.0, −0.6)      −0.5 (−0.7, −0.3)
  Change vs sitagliptin[2](#dom12832-note-0006){ref-type="fn"}   −0.2 (−0.5, 0.0)       

Values are mean ± standard deviation unless otherwise noted.

To convert mmol/L to mg/dL multiply by 18.

LS mean (95% CI).

Difference in LS means (95% CI).

After 24 weeks of treatment, omarigliptin compared with sitagliptin provided a similar reduction in FPG (Figure [1](#dom12832-fig-0001){ref-type="fig"}B and Table [2](#dom12832-tbl-0002){ref-type="table-wrap"}). In both treatment groups, a near‐maximum reduction from baseline in FPG was observed at week 6, and the treatment effect was maintained throughout the remainder of the treatment period (Figure [1](#dom12832-fig-0001){ref-type="fig"}B).

After 24 weeks of treatment, the percentages of patients at HbA1c goals of \<7.0% and \<6.5% were similar in the two treatment groups. At week 24 the percentages of patients with HbA1c \<7.0% were 54.4 (95% CI 48.8, 59.9) and 52.4 (95% CI 46.8, 57.9) in the omarigliptin and sitagliptin groups, respectively, while for those with HbA1c \<6.5% they were 28.8 (95% CI 24.0, 34.1) and 24.4 (95% CI 19.9, 29.5; Figure S3).

Five patients (1.6%) in the omarigliptin group and 6 (1.9%) in the placebo group received rescue therapy at or before week 24 and the time‐to‐rescue was similar in the 2 treatment groups.

3.3. Safety and tolerability {#dom12832-sec-0016}
----------------------------

The incidence rates of overall AEs, AEs assessed by the investigator as drug‐related and serious AEs were similar between the omarigliptin and sitagliptin groups (Table [3](#dom12832-tbl-0003){ref-type="table-wrap"}). There were no reported AEs of pancreatitis and no adjudication‐confirmed events of pancreatitis in either treatment group. One death attributable to myocardial infarction was reported in a patient in the sitagliptin group; the patient had a history of ischaemic heart disease.

###### 

Adverse events summary

                                                                     **Omarigliptin**    **Sitagliptin**  
  ------------------------------------------------------------------ ------------------ ----------------- ---------------------------------------------------------
  With one or more                                                                                        
  AEs                                                                117 (36.3)            130 (40.6)     −4.3 (−11.8, 3.2)
  Drug‐related[2](#dom12832-note-0008){ref-type="fn"} AEs            12 (3.7)               12 (3.8)      0.0 (−3.2, 3.1)
  Serious AEs                                                        11 (3.4)                9 (2.8)      0.6 (−2.3, 3.5)
  Serious drug‐related[2](#dom12832-note-0008){ref-type="fn"} AEs    0 (0.0)                 0 (0.0)      0.0
  Who died                                                           0 (0.0)                 1 (0.3)      −0.3
  Who discontinued due to                                                                                 
  An AE                                                              3 (0.9)                 7 (2.2)      −1.3 (−3.6, 0.8)
  A drug‐related[2](#dom12832-note-0008){ref-type="fn"} AE           0 (0.0)                 1 (0.3)      −0.3
  A serious AE                                                       1 (0.3)                 2 (0.6)      −0.3
  A serious drug‐related[2](#dom12832-note-0008){ref-type="fn"} AE   0 (0.0)                 0 (0.0)      0.0
  With one or more AE of hypoglycaemia                               12 (3.7)               15 (4.7)      −1.0 (−4.3, 2.3)
  Symptomatic[3](#dom12832-note-0009){ref-type="fn"}                 10 (3.1)               13 (4.1)      −1.0 (−4.1, 2.1)[4](#dom12832-note-0010){ref-type="fn"}
  Asymptomatic[5](#dom12832-note-0011){ref-type="fn"}                5 (1.6)                 3 (0.9)      0.6 (−1.4, 2.8)

Difference in % vs sitagliptin; estimate (95% CI) was computed only for those endpoints with at least 4 patients having events in ≥1 treatment groups.

Assessed by the investigator as related to study drug.

Symptomatic hypoglycaemia: episode with clinical symptoms attributed to hypoglycaemia, without regard to glucose level.

P = .515.

Asymptomatic hypoglycaemia: glucose values ≤3.9 mmol/L without symptoms.

Specific AEs with an incidence ≥2% in ≥1 treatment group are shown in Table [4](#dom12832-tbl-0004){ref-type="table-wrap"}. All of the AEs of lipase increased as well as amylase increased (incidence \<2%) were non‐serious and none led to discontinuation from study medication. One patient in the omarigliptin group had 2 non‐serious AEs of tongue oedema, which were not associated with respiratory distress and which were adjudicated and confirmed to be angioedema (a prespecified hypersensitivity AE). The incidence of patients reporting ≥ 1 AE of hypoglycaemia (symptomatic or asymptomatic) was similar in the two treatment groups (Table [3](#dom12832-tbl-0003){ref-type="table-wrap"}). There were no events of hypoglycaemia that required medical assistance; one patient in the omarigliptin group had an event of hypoglycaemia that required non‐medical assistance.

###### 

Specific AEs with an incidence ≥2% in ≥1 treatment group by system organ class

                                                               **Omarigliptin**   **Sitagliptin**
  ------------------------------------------------------------ ------------------ -----------------
  **Gastrointestinal disorders, n (%)**                                           
  Diarrhoea                                                    3 (0.9)            9 (2.8)
  **Infections and infestations, n (%)**                                          
  Influenza                                                    1 (0.3)            7 (2.2)
  Upper respiratory tract infection                            13 (4.0)           12 (3.8)
  Urinary tract infection                                      4 (1.2)            9 (2.8)
  **Investigations, n (%)**                                                       
  Lipase increased                                             8 (2.5)            13 (4.1)
  **Metabolism and nutrition disorders, n (%)**                                   
  Hypoglycaemia                                                12 (3.7)           15 (4.7)
  **Musculoskeletal and connective tissue disorders, n (%)**                      
  Back pain                                                    8 (2.5)            2 (0.6)

There were no clinically meaningful changes from baseline in laboratory safety measures or predefined limits of change. Small increases from baseline at week 24 in mean serum amylase and lipase levels were observed in both treatment groups; the magnitude of the increase was similar in both groups. Both baseline and week 24 mean amylase and lipase values were within normal laboratory limits for both the sitagliptin and omarigliptin groups. At baseline, 11.2% of patients in the omarigliptin group and 11.6% of patients in the sitagliptin group had lipase values greater than the central laboratory upper limit of normal (\>ULN). On treatment, at weeks 6, 12, 18 and 24, the incidence of patients with lipase \>ULN ranged from 17.4% to 21.2% in the omarigliptin group and 14.1% to 20.4% in the sitagliptin group (Table S1). Lower incidences of amylase \>ULN at baseline and on treatment were observed (Table S1). In patients who had a lipase value \>ULN at baseline or who had values \>ULN during the treatment period, fluctuations above and below the ULN were commonly observed.

There were no clinically meaningful changes from baseline in heart rate, blood pressure or ECG intervals (including QTc). At week 24, there was a small decrease from baseline in body weight in both treatment groups (LS mean change from baseline of −0.7 kg \[95% CI −1.2, −0.3\] and −0.9 kg \[95% CI −1.3, −0.4\] in the omarigliptin and sitagliptin groups, respectively).

4. DISCUSSION {#dom12832-sec-0017}
=============

The present study showed that in patients with T2DM and inadequate glycaemic control with metformin, the addition of once‐weekly omarigliptin 25 mg provided similar reductions in HbA1c (meeting non‐inferiority criteria) and FPG, with a similar time course to that of daily administered sitagliptin 100 mg. Treatment with omarigliptin also resulted in a similar proportion of patients meeting glycaemic goals to that seen with sitagliptin.

The observed glycaemic efficacy in the present study indirectly serves as further evidence of the feasibility of providing DPP‐4 inhibition over the period of 1 week with a single once‐weekly dose that is similar to that which can be achieved with daily administration. The present results also provide further confirmation that the 25‐mg once weekly dose of omarigliptin is an appropriate dose for achieving clinical efficacy similar to that of a daily DPP‐4 inhibitor. The extent of HbA1c‐lowering from baseline observed in both treatment groups reflects the mild mean baseline hyperglycaemia in this study. It is well recognized that the extent of HbA1c‐lowering across glucose‐lowering therapies, irrespective of class, is proportional to the baseline HbA1c[6](#dom12832-bib-0006){ref-type="ref"}; consistent with this, larger reductions were observed in patients with higher baseline HbA1c values.

Previous studies have shown the efficacy and safety of omarigliptin 25 mg once weekly as monotherapy for the treatment of T2DM.[7](#dom12832-bib-0007){ref-type="ref"}, [8](#dom12832-bib-0008){ref-type="ref"} The present study extends the experience with omarigliptin on a background of metformin.

The analysis of AEs and laboratory variables showed that omarigliptin was generally well tolerated, and no safety signals emerged that would suggest omarigliptin has a safety profile that distinguishes it from other presently marketed DPP‐4 inhibitors, including sitagliptin. The incidence of symptomatic hypoglycaemia was low in both treatment groups, which is consistent with the profile of DPP‐4 inhibitors when they are administered as monotherapy or co‐administered with agents that are not associated with hypoglycaemia, such as metformin. The incidence and characteristics (duration) of the hypoglycaemia events reported in association with the agent dosed once weekly (omarigliptin) were not distinguishable from those of the agent dosed once daily (sitagliptin), consistent with the glucose‐dependent mechanism (DPP‐4 inhibition) of both agents.

There were no clinically meaningful changes in laboratory safety measures for either agent. Small increases in lipase \>ULN were observed in patients in both the sitagliptin and omarigliptin groups. Patients with elevations of lipase \>ULN at baseline, as well as those with elevations on treatment, frequently had subsequent values that fluctuated between normal and \>ULN. In the present study there were no cases of investigator‐reported or adjudication‐confirmed pancreatitis in either treatment group. The modest and transient elevations in lipase levels observed in both groups were not associated with any evident increase in the occurrence of AEs of abdominal pain, abdominal discomfort or nausea or vomiting and no patients discontinued the study because of those AEs. The presence of baseline amylase and lipase values \>ULN in asymptomatic patients, prior to their first dose of study medication, indicates that asymptomatic elevations in amylase and lipase levels are phenomena observed in a certain percentage of patients with T2DM, which appears to be slightly accentuated with incretin therapy, as has previously been reported.[9](#dom12832-bib-0009){ref-type="ref"}, [10](#dom12832-bib-0010){ref-type="ref"} Taken together, the small increases in amylase and lipase observed with sitagliptin and omarigliptin are unlikely to be clinically relevant.

In summary, once‐weekly treatment with omarigliptin 25 mg provided improvement in glycaemic control that was non‐inferior to daily dosed sitagliptin 100 mg and provided clinically meaningful glycaemic control without increasing the risk of hypoglycaemia and with a safety profile similar to that of sitagliptin. These results suggest once‐weekly omarigliptin may provide a valuable oral therapeutic option for the treatment of T2DM.
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###### 

**Table S1.** Incidence of subjects with amylase or lipase values \> upper limit of normal (ULN), \>1.5 ULN or \>3X ULN.

**Figure S1.** Study design; T2DM = type 2 diabetes mellitus; q.w. = once weekly; q.d. = once daily; R = randomization.

**Figure S2.** Disposition of subjects.

**Figure S3.** Percentage of subjects at HbA1c goals of \<7.0% or \<6.5% at Week 24. Percentages were estimated using standard multiple imputation techniques.

###### 

Click here for additional data file.
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